Citations

Clear

114 citation(s) found for "Scott, Michael".

Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019
Kelly, William Kevin, Cheng, Heather H. , Cookson, Michael S. , Dahut, William L. , Weissman, Scott M., Soule, Howard R. , Petrylak, Daniel P. , Dicker, Adam P. , AlDubayan, Saud H. , Pettaway, Curtis A. , Daly, Mary B., Mohler, James L. , Parsons, J. Kellogg , Pilarski, Robert , Blanco, Amie , Woodson, Ashley, Taplin, Mary-Ellen, Polascik, Thomas J. , Hyatt, Colette, Feng, Felix Y. , Mullane, Michael P., Powers, Jacqueline, Concepcion, Raoul S. , Lin, Daniel W. , Wender, Richard C. , Mark, James Ryan , Costello, Anthony J. , Isaacs, William B. , Xu, Jianfeng , Weitzel, Jeffrey N. , Andriole, Gerald L. , Beltran, Himisha , Briganti, Alberto , Byrne, Lindsey , Calvaresi, Anne, Chandrasekar, Thenappan , Chen, David Y.T. , Dobi, Albert , Crawford, E. David , Eastham, James A., Eggener, Scott E. , Freedman, Matthew L. , Garnick, Marc B. , Gomella, Patrick T. , Handley, Nathan , Hurwitz, Mark , Izes, Joseph K. , Karnes, R. Jeffrey , Lallas, Costas D. , Languino, Lucia R. , Loughlin, Kevin R. , Lu‐Yao, Grace , Malkowicz, S. Bruce, Mann, Mark, Mille, Patrick , Miner, Martin , Morgan, Todd M. , Mucci, Lorelei A. , Nielsen, Sarah M. , O’Neil, Brock , Pinover, Wayne H., Pinto, Peter A. , Poage, Wendy, Raj, Ganesh V. , Ryan, Charles J. , Schiewer, Matthew J. , Szymaniak, Brittany M. , Tester, William , Trabulsi, Edouard J. , Vapiwala, Neha , Gomella, Leonard G. , Weitzel, Jeffrey N , Morgan, Todd M , Cheng, Heather H , Dicker, Adam P , Giri, Veda N. , Knudsen, Karen E. , Cooney, Kathleen A. , Toland, Amanda Ewart , Pritchard, Colin C. , Carroll, Peter R , Rahm, Alanna Kulchak , Taplin, Mary‐Ellen , Helfand, Brian T. , Morgans, Alicia K. , Burnett, Arthur L. “Bud” , Sartor, Oliver , Den, Robert B. , Loeb, Stacy , López, Ana María , Moreno, Jose, Myers, Ronald E. , Rebbeck, Timothy R. , Sandler, Howard M. , Scott, E. Michael D., Yu, Evan Y , Zeigler-Johnson, Charnita M

Mayo Clinic

Journal of Clinical Oncology | June 9, 2020 | Volume: 38 | Issue: 24 | Pages: 2798-2811

10.1200/jco.20.00046 | PMID 32516092 Get It

PURPOSE Germline testing (GT) is a central feature of prostate cancer (PCA) treatment, management, and hereditary cancer assessment. Critical needs include optimized multigene testing strategies that incorporate evolving genetic data, consistency in GT indications and management, and alternate genetic evaluation models that address the rising demand for genetic services. METHODS A multidisciplinary consensus conference that included experts, stakeholders, and national organization leaders was convened in response to current practice challenges and to develop a genetic implementation framework. Evidence review informed questions using the modified Delphi model. The final framework included criteria with strong (> 75%) agreement (Recommend) or moderate (50% to 74%) agreement (Consider). RESULTS Large germline panels and somatic testing were recommended for metastatic PCA. Reflex testing—initial testing of priority genes followed by expanded testing—was suggested for multiple scenarios. Metastatic disease or family history suggestive of hereditary PCA was recommended for GT. Additional family history and pathologic criteria garnered moderate consensus. Priority genes to test for metastatic disease treatment included BRCA2, BRCA1, and mismatch repair genes, with broader testing, such as ATM, for clinical trial eligibility. BRCA2 was recommended for active surveillance discussions. Screening starting at age 40 years or 10 years before the youngest PCA diagnosis in a family was recommended for BRCA2 carriers, with consideration in HOXB13, BRCA1, ATM, and mismatch repair carriers. Collaborative (point-of-care) evaluation models between health care and genetic providers was endorsed to address the genetic counseling shortage. The genetic evaluation framework included optimal pretest informed consent, post-test discussion, cascade testing, and technology-based approaches. CONCLUSION This multidisciplinary, consensus-driven PCA genetic implementation framework provides novel guidance to clinicians and patients tailored to the precision era. Multiple research, education, and policy needs remain of importance.
Four-dimensional Flow Magnetic Resonance Imaging Quantification of Blood Flow in Bicuspid Aortic Valve
Gordon, Daniel , Abbasi, Muhannad , Lee, Jeesoo , Sarnari, Roberto, Sojoudi, Alireza , Wei, Qiao, Scott, Michael , Allen, Bradley D. , Blaisdell, Julie , Carr, James , Markl, Michael , Collins, Jeremy D. , Allen, Bradley A , Markl, Michael , Wei, Qiao

Mayo Clinic

Journal of Thoracic Imaging | May 26, 2020 | Volume: 35 | Issue: 6 | Pages: 383-388

10.1097/rti.0000000000000535 | PMID 32453278 Get It

Background: Four-dimensional (D) flow magnetic resonance imaging (MRI) is limited by time-consuming and nonstandardized data analysis. We aimed to test the efficiency and interobserver reproducibility of a dedicated 4D flow MRI analysis workflow. Materials and Methods: Thirty retrospectively identified patients with bicuspid aortic valve (BAV, age=47.8±11.8 y, 9 male) and 30 healthy controls (age=48.8±12.5 y, 21 male) underwent Aortic 4D flow MRI using 1.5 and 3 T MRI systems. Two independent readers performed 4D flow analysis on a dedicated workstation including preprocessing, aorta segmentation, and placement of four 2D planes throughout the aorta for quantification of net flow, peak velocity, and regurgitant fraction. 3D flow visualization using streamlines was used to grade aortic valve outflow jets and extent of helical flow. Results: 4D flow analysis workflow time for both observers: 5.0±1.4 minutes per case (range=3 to 10 min). Valve outflow jets and flow derangement was visible in all 30 BAV patients (both observers). Net flow, peak velocity, and regurgitant fraction was significantly elevated in BAV patients compared with controls except for regurgitant fraction in plane 4 (91.1±29.7 vs. 62.6±19.6 mL/s, 37.1% difference; 121.7±49.7 vs. 90.9±26.4 cm/s, 28.9% difference; 9.3±10.1% vs. 2.0±3.4%, 128.0% difference, respectively; P <0.001). Excellent intraclass correlation coefficient agreement for net flow: 0.979, peak velocity: 0.931, and regurgitant fraction: 0.928. Conclusion: Our study demonstrates the potential of an efficient data analysis workflow to perform standardized 4D flow MRI processing in under 10 minutes and with good-to-excellent reproducibility for flow and velocity quantification in the thoracic aorta.
The Truly Functional Heart Team: The Devil Is in the Details
Holmes, David R. , Mack, Michael J.

Mayo Clinic

Journal of the American Heart Association | April 20, 2020 | Volume: 9 | Issue: 8 | Pages: No page available

10.1161/jaha.120.016306 | PMID 32308107 Get It

Outcomes of Transcatheter Aortic Valve Replacement in Patients With Bicuspid Aortic Valve Disease
Halim, Sharif, Edwards, Fred H., Dai, David , Li, Zhuokai , Mack, Michael J. , Holmes, David R. , Tuzcu, E. Murat , Thourani, Vinod H. , Harrison, J. Kevin , Brennan, James M. , Douglas, Pamela S. , Douglas, Pamela S

Mayo Clinic

Circulation | March 18, 2020 | Volume: 141 | Issue: 13 | Pages: 1071-1079

10.1161/circulationaha.119.040333 | PMID 32098500 Get It

Background: Patients with bicuspid aortic valve (AV) stenosis were excluded from the pivotal evaluations of transcatheter AV replacement (TAVR) devices. We sought to evaluate the outcomes of TAVR in patients with bicuspid AV stenosis in comparison with those with tricuspid AV stenosis. Methods: We used data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry (November 2011 through November 2018) to determine device success, procedural outcomes, post-TAVR valve performance, and in-hospital clinical outcomes (mortality, stroke, and major bleeding) according to valve morphology (bicuspid versus tricuspid). Results were stratified by older and current (Sapien 3 and Evolut R) generation valve prostheses. Medicare administrative claims were used to evaluate mortality and stroke to 1 year among eligible individuals (≥65 years). Results: After exclusions, there were 170 959 eligible procedures at 593 sites during the specified interval. Of these, 5412 TAVR procedures (3.2%) were performed in patients with bicuspid AV, including 3705 with current-generation devices. In comparison with patients with tricuspid valves, patients with bicuspid AV were younger and had a lower Society of Thoracic Surgeons Predicted Risk of Operative Mortality score. When current-generation devices were used to treat patients with bicuspid AV, device success increased (93.5 versus 96.3; P =0.001) and the incidence of 2+ aortic insufficiency declined (14.0% versus 2.7%; P <0.001) in comparison with older-generation devices. With current-generation devices, device success was slightly lower in the bicuspid (versus tricuspid) AV group (96.3% in bicuspid versus 97.4% in tricuspid, P =0.07), with a slightly higher incidence of residual moderate or severe aortic insufficiency among patients with bicuspid AV (2.7% versus 2.1%; P <0.001). A lower 1-year adjusted risk of mortality (hazard ratio, 0.88 [95% CI, 0.78–0.99]) was observed for patients with bicuspid AV versus patients with tricuspid AV in the Medicare-linked cohort, whereas no difference was observed in the 1-year adjusted risk of stroke (hazard ratio, 1.14 [95% CI, 0.94–1.39]). Conclusions: Using current-generation devices, procedural, postprocedural, and 1-year outcomes were comparable following TAVR for bicuspid AV versus tricuspid AV disease. With newer-generation devices, TAVR is a viable treatment option for patients with bicuspid AV disease.
Thirty-Day Outcomes of Transcatheter Mitral Valve Replacement for Degenerated Mitral Bioprostheses (Valve-in-Valve), Failed Surgical Rings (Valve-in-Ring), and Native Valve With Severe Mitral Annular Calcification (Valve-in-Mitral Annular Calcification) in
Vemulapalli, Sreekanth , Xiang, Qun, Wang, Dee Dee , Eleid, Mackram F. , Sandhu, Gurpreet S. , Salinger, Michael H., Russell, Hyde M., Kodali, Susheel , Dvir, Danny , Russo, Mark J., Fang, Kenith, Coylewright, Megan , Shah, Pinak , Babaliaros, Vasilis , Khan, Jaffar M. , Tommaso, Carl L. , Saucedo, Jorge , Makkar, Rajj, Mack, Michael J. , Holmes, David R. , Leon, Martin B. , Bapat, Vinayak , Thourani, Vinod H. , Rihal, Charanjit S. , O’Neill, William, Feldman, Ted , Douglas, Pamela S. , Eleid, Mackram, Cabalka, Allison K. , Rihal, Charanjit, Wang, Dee Dee , Douglas, Pamela S , Guerrero, Mayra , Greenbaum, Adam B. , George, Isaac , Whisenant, Brian K. , Pershad, Ashish , Shah, Pinak , Kar, Saibal , Makkar, Raj , Rihal, Charanjit S.

Mayo Clinic

Circulation: Cardiovascular Interventions | March 6, 2020 | Volume: 13 | Issue: 3 | Pages: No page available

10.1161/circinterventions.119.008425 | PMID 32138529 Get It

Background: Transcatheter mitral valve replacement using aortic transcatheter heart valves has recently become an alternative for patients with degenerated mitral bioprostheses, failed surgical repairs with annuloplasty rings or severe mitral annular calcification who are poor surgical candidates. Outcomes of these procedures are collected in the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry. A comprehensive analysis of mitral valve-in-valve (MViV), mitral valve-in-ring (MViR), and valve-in-mitral annular calcification (ViMAC) outcomes has not been performed. We sought to evaluate short-term outcomes of early experience with MViV, MViR, and ViMAC in the United States. Methods: Retrospective analysis of data from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Results: Nine hundred three high-risk patients (median Society of Thoracic Surgeons score 10%) underwent MViV (n=680), MViR (n=123), or ViMAC (n=100) between March 2013 and June 2017 at 172 hospitals. Median age was 75 years, 59.2% female. Technical and procedural success were higher in MViV. Left ventricular outflow tract obstruction occurred more frequently with ViMAC (ViMAC=10%, MViR=4.9%, MViV=0.7%; P <0.001). In-hospital mortality (MViV=6.3%, MViR=9%, ViMAC=18%; P =0.004) and 30-day mortality (MViV=8.1%, MViR=11.5%, ViMAC=21.8%; P =0.003) were higher in ViMAC. At 30-day follow-up, median mean mitral valve gradient was 7 mm Hg, most patients (96.7%) had mitral regurgitation grade ≤1 (+) and were in New York Heart Association class I to II (81.7%). Conclusions: MViV using aortic balloon-expandable transcatheter heart valves is associated with a low complication rate, a 30-day mortality lower than predicted by the Society of Thoracic Surgeons score, and superior short-term outcomes than MViR and ViMAC. At 30 days, patients in all groups experienced improvement of symptoms, and valve performance remained stable. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02245763.
In Reply
Dowdy, Sean C. , Kalogera, Eleftheria , Scott, Michael

Mayo Clinic

Obstetrics & Gynecology | December 19, 2019 | Volume: 135 | Issue: 1 | Pages: 219-220

10.1097/aog.0000000000003639 | PMID 31856109 Get It

Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes
Bakaeen, Faisal G. , Farkouh, Michael E. , Holmes, David R. , Nakamura, Sunao , Head, Stuart J., Park, Seung‐Jung , Mack, Michael J. , Stone, Gregg W. , Tam, Derrick Y. , Vallely, Michael P. , Gaudino, Mario , Angiolillo, Dominick J. , Franco, Antonino Di , Capodanno, Davide , Fremes, Stephen E. , Girard, Leonard N , Serruys, Patrick W. , Ruel, Marc , Taggart, David P

Mayo Clinic

Journal of the American Heart Association | June 27, 2019 | Volume: 8 | Issue: 13 | Pages: No page available

10.1161/jaha.119.013032 | PMID 31242821 Get It

The Medical Device Innovation Consortium and Its Goal to Further the Efficiency of Early Feasibility Studies in the United States
Holmes, David R. , Mack, Michael J. , Leon, Martin B. , Kaplan, Aaron V. , Hance, Robert “Chip”

Mayo Clinic

Journal of Endovascular Therapy | May 20, 2019 | Volume: 26 | Issue: 3 | Pages: 423-424

10.1177/1526602819845625 | PMID 31106689 Get It

Rational Dispersion for the Introduction of Transcatheter Mitral Valve Repair Into Clinical Practice
Holmes, David R. , Mack, Michael J.

Mayo Clinic

JAMA | March 15, 2019 | Volume: 321 | Issue: 11 | Pages: 1043

10.1001/jama.2019.1542 | PMID 30874762 Get It